Wendy A. Szymczak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wendy A. Szymczak has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
- Erika P. Orner
Montefiore Medical Center , Bronx, New York
9 shared publications Priya Nori
Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center
6 shared publicationsMichael H. Levi
Department of Pathology, Montefiore Medical Center
5 shared publications- D. Yitzchak Goldstein
Department of Pathology, Montefiore Medical Center
4 shared publications Yi Guo
Department of Pharmacy, Montefiore Medical Centers
4 shared publicationsAmy S. Fox
Department of Pathology, Albert Einstein College of Medicine, Bronx, New York, USA
3 shared publications
Latest Publications
- Open Access
- 20 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (9) , e0084125
Luciferase reporter mycobacteriophage (TM4:: GeNL ) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex
Mycobacterium abscessus (MAB) infections are challenging to treat due to high-level resistance to anti-tuberculosis drugs, carbapenems, fluoroquinolones, and tetracyclines. Clarithromycin and amikacin are considered cornerstone drugs for MAB treatment due to their superior efficacy; however, assessing clarithromycin susceptibility typically takes 7 to 14 days because of inducible macrolide resistance. We developed a 48 h luciferase reporter mycobacteriophage drug susceptibility testing (LRM-DST) assay using TM4:: GeNL to evaluate MAB drug susceptibility. For this proof-of-principle study, we performed DST on 26 MAB clinical isolates using TM4:: GeNL and Sensititre RAPMYCO2 plates. Genome sequencing was performed to identify the MAB sub-species and for understanding intrinsic and acquired drug resistance mechanisms. We detected clarithromycin resistance in 12/26 (46%) by both Sensititre and LRM-DST. All clarithromycin-resistant isolates carried full-length inducible erythromycin ribosomal methylase-41 [ erm(41 )] gene, and none had rrl (23S rRNA) mutations. Amikacin resistance or intermediate amikacin resistance was detected in 6/26 (23%) isolates. Mutations in the rrs (16S rRNA) gene at positions 1375A > G ( E. coli 1408A > G) conferred amikacin resistance in four isolates; however, no mutations were identified in two of the amikacin intermediate-resistant isolates. LRM-DST results were in 100% and 92.3% concordance with Sensititre DST results of clarithromycin (kappa coefficient, 1.0; 95% confidence interval [CI], 0.84 to 1.0) and amikacin (kappa coefficient, 0.752; 95% confidence interval [CI], 0.43 to 1.0). In addition, LRM-DST results for bedaquiline, moxifloxacin, imipenem, linezolid, and cefoxitin correlated well with Sensititre DST. Our findings suggest that LRM-DST can provide reliable phenotypic MAB-DST information in 48 h for prompt clinical management. IMPORTANCE: Mycobacterium abscessus (MAB) is a notorious human pathogen causing severe infections in individuals with cystic fibrosis and immunocompromised patients. Treatment options for MAB are very limited as they are resistant to multiple drugs through intrinsic and acquired resistance mechanisms. While macrolides and amikacin are the key drugs in the fight against MAB infections, emerging drug resistance is compromising their efficacy. Current growth-based drug susceptibility testing (DST) method takes 7 to 14 days to identify clarithromycin susceptibility due to the presence of inducible macrolide resistance and 3 to 5 days for other drugs. We developed a novel luciferase reporter mycobacteriophage (LRM) based phenotypic DST method using TM4:: GeNL to assess MAB drug susceptibility based on metabolic inhibition rather than growth. LRM-DST significantly reduces the DST turnaround time to 48 h and provides rapid assessment of MAB susceptibility to drugs, including inducible macrolide resistance, thereby accelerating the treatment process and improving patient outcomes.
- 20 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (9) , e0084125
Open AccessLuciferase reporter mycobacteriophage (TM4:: GeNL ) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex
Mycobacterium abscessus (MAB) infections are challenging to treat due to high-level resistance to anti-tuberculosis drugs, carbapenems, fluoroquinolones, and tetracyclines. Clarithromycin and amikacin are considered cornerstone drugs for MAB treatment due to their superior efficacy; however, assessing clarithromycin susceptibility typically takes 7 to 14 days because of inducible macrolide resistance. We developed a 48 h luciferase reporter mycobacteriophage drug susceptibility testing (LRM-DST) assay using TM4:: GeNL to evaluate MAB drug susceptibility. For this proof-of-principle study, we performed DST on 26 MAB clinical isolates using TM4:: GeNL and Sensititre RAPMYCO2 plates. Genome sequencing was performed to identify the MAB sub-species and for understanding intrinsic and acquired drug resistance mechanisms. We detected clarithromycin resistance in 12/26 (46%) by both Sensititre and LRM-DST. All clarithromycin-resistant isolates carried full-length inducible erythromycin ribosomal methylase-41 [ erm(41 )] gene, and none had rrl (23S rRNA) mutations. Amikacin resistance or intermediate amikacin resistance was detected in 6/26 (23%) isolates. Mutations in the rrs (16S rRNA) gene at positions 1375A > G ( E. coli 1408A > G) conferred amikacin resistance in four isolates; however, no mutations were identified in two of the amikacin intermediate-resistant isolates. LRM-DST results were in 100% and 92.3% concordance with Sensititre DST results of clarithromycin (kappa coefficient, 1.0; 95% confidence interval [CI], 0.84 to 1.0) and amikacin (kappa coefficient, 0.752; 95% confidence interval [CI], 0.43 to 1.0). In addition, LRM-DST results for bedaquiline, moxifloxacin, imipenem, linezolid, and cefoxitin correlated well with Sensititre DST. Our findings suggest that LRM-DST can provide reliable phenotypic MAB-DST information in 48 h for prompt clinical management. IMPORTANCE: Mycobacterium abscessus (MAB) is a notorious human pathogen causing severe infections in individuals with cystic fibrosis and immunocompromised patients. Treatment options for MAB are very limited as they are resistant to multiple drugs through intrinsic and acquired resistance mechanisms. While macrolides and amikacin are the key drugs in the fight against MAB infections, emerging drug resistance is compromising their efficacy. Current growth-based drug susceptibility testing (DST) method takes 7 to 14 days to identify clarithromycin susceptibility due to the presence of inducible macrolide resistance and 3 to 5 days for other drugs. We developed a novel luciferase reporter mycobacteriophage (LRM) based phenotypic DST method using TM4:: GeNL to assess MAB drug susceptibility based on metabolic inhibition rather than growth. LRM-DST significantly reduces the DST turnaround time to 48 h and provides rapid assessment of MAB susceptibility to drugs, including inducible macrolide resistance, thereby accelerating the treatment process and improving patient outcomes.
- Open Access
- 13 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (8) , e0198324
Multicenter evaluation of the QIAstat-Dx Gastrointestinal Panel 2, a multiplex PCR platform for the diagnosis of acute gastroenteritis
The QIAstat-Dx Gastrointestinal Panel 2 (GI2 Panel) is a sample-to-answer multiplex PCR instrument that can detect 17 targets in a run time of about 80 minutes. The performance of the QIAstat-Dx GI2 Panel was evaluated by testing 1,939 prospective, 119 prospectively collected and then archived positive clinical samples and 750 retrospective clinical specimens across 13 sites in Europe and the United States. Specimens tested included bulk stool samples preserved in modified Cary-Blair transport medium. For most targets, results were compared to those of the FilmArray GI panel (13/17), and discordant results were adjudicated with a third assay. For the remaining targets (4/17), a composite comparator method was used, which included three comparator assays for each target. Before discordant resolution, the QIAstat-Dx GI2 Panel positive percent agreement (PPA) was 95% or greater for 5/17 targets ( Campylobacter , E. coli O157, Cryptosporidium, Cyclospora cayetanensis, and Giardia lamblia ) and 90% or greater for 11/17 targets: adenovirus F40/F41, astrovirus, norovirus GI/GII, rotavirus A, Plesiomonas shigelloides , enteropathogenic Escherichia coli , enterotoxigenic E. coli , Salmonella , Yersinia enterocolitica, Shiga-like toxin E. coli (STEC) stx1/stx2 , and Shigella /enteroinvasive E. coli . No cases of Entamoeba histolytica were encountered during the clinical study. The negative percent agreement (NPA) was >98.9% for all QIAstat-Dx GI2 Panel targets. The three most common pathogens identified in single and co-infections were enteropathogenic E. coli (9.9%), Campylobacter (5.2%), and norovirus GI/GII (3.1%). In summary, this clinical study examined more than 2,800 samples from Europe and the U.S. using the QIAstat-Dx GI2 Panel and identified 90%–100% PPA and 99% NPA for its 17 targets. IMPORTANCE: The manuscript highlights the significance and impact of the QIAstat-Dx GI2 Panel, a sample-to-answer multiplex PCR instrument capable of detecting 17 targets in approximately 80 minutes. This comprehensive clinical study, conducted across 13 sites in Europe and the United States, evaluated the performance of the panel using over 2,800 clinical samples. The results demonstrate a high accuracy of the QIAstat-Dx GI2 panel, with a PPA equal to or higher than 90% for all targets and an NPA greater than 98.9% for all targets. These findings underscore the reliability and effectiveness of the GI2 panel in the rapid and precise detection of gastrointestinal pathogens, which is crucial for timely diagnosis and treatment of infections.
- 13 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (8) , e0198324
Open AccessMulticenter evaluation of the QIAstat-Dx Gastrointestinal Panel 2, a multiplex PCR platform for the diagnosis of acute gastroenteritis
The QIAstat-Dx Gastrointestinal Panel 2 (GI2 Panel) is a sample-to-answer multiplex PCR instrument that can detect 17 targets in a run time of about 80 minutes. The performance of the QIAstat-Dx GI2 Panel was evaluated by testing 1,939 prospective, 119 prospectively collected and then archived positive clinical samples and 750 retrospective clinical specimens across 13 sites in Europe and the United States. Specimens tested included bulk stool samples preserved in modified Cary-Blair transport medium. For most targets, results were compared to those of the FilmArray GI panel (13/17), and discordant results were adjudicated with a third assay. For the remaining targets (4/17), a composite comparator method was used, which included three comparator assays for each target. Before discordant resolution, the QIAstat-Dx GI2 Panel positive percent agreement (PPA) was 95% or greater for 5/17 targets ( Campylobacter , E. coli O157, Cryptosporidium, Cyclospora cayetanensis, and Giardia lamblia ) and 90% or greater for 11/17 targets: adenovirus F40/F41, astrovirus, norovirus GI/GII, rotavirus A, Plesiomonas shigelloides , enteropathogenic Escherichia coli , enterotoxigenic E. coli , Salmonella , Yersinia enterocolitica, Shiga-like toxin E. coli (STEC) stx1/stx2 , and Shigella /enteroinvasive E. coli . No cases of Entamoeba histolytica were encountered during the clinical study. The negative percent agreement (NPA) was >98.9% for all QIAstat-Dx GI2 Panel targets. The three most common pathogens identified in single and co-infections were enteropathogenic E. coli (9.9%), Campylobacter (5.2%), and norovirus GI/GII (3.1%). In summary, this clinical study examined more than 2,800 samples from Europe and the U.S. using the QIAstat-Dx GI2 Panel and identified 90%–100% PPA and 99% NPA for its 17 targets. IMPORTANCE: The manuscript highlights the significance and impact of the QIAstat-Dx GI2 Panel, a sample-to-answer multiplex PCR instrument capable of detecting 17 targets in approximately 80 minutes. This comprehensive clinical study, conducted across 13 sites in Europe and the United States, evaluated the performance of the panel using over 2,800 clinical samples. The results demonstrate a high accuracy of the QIAstat-Dx GI2 panel, with a PPA equal to or higher than 90% for all targets and an NPA greater than 98.9% for all targets. These findings underscore the reliability and effectiveness of the GI2 panel in the rapid and precise detection of gastrointestinal pathogens, which is crucial for timely diagnosis and treatment of infections.
- Open Access
- 1 April 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (4)
Performance characteristics of an automated, high-throughput RT-PCR assay for the detection of Candida auris on 3-point and nasal swabs
Candida auris is a multidrug-resistant yeast responsible for invasive infections with high mortality rates, primarily spread through prolonged colonization on biotic and abiotic surfaces and traveling. Effective control necessitates comprehensive screening protocols, as recommended by the Centers for Disease Control and Prevention, which endorses a real-time polymerase chain reaction-based assay for C. auris screening. This study evaluates the performance of this assay on the Hologic Panther Fusion System using nasal and 3-point swab specimens (nares/axilla/groin) compared with culture. The assay was assessed for accuracy, sensitivity, specificity, and reproducibility, alongside an evaluation of probe primer reagent (PPR) onboard stability over 30 working days. Analytical sensitivity studies determined limits of detection of 1.95 Log CFU/mL for nasal swabs and 2.18 Log CFU/mL for 3-point swabs, both with >95.0% confidence intervals. The assay demonstrated 100% specificity ( n = 25), with no false positives from genetically similar or clinically relevant species, and no significant interference from co-infecting microbes on cycle threshold (CT) values. Both swab types exhibited high intra- and inter-reproducibility, with low coefficients of variation (1.79% and 1.06%, respectively). The assay detected C. auris in 100% of 108 spiked-positive samples across both swab types. Clinical analysis showed 100% concordance with culture for 3-point swabs. Additionally, the nasal swab method showed 96.0% overall agreement, with 86.2% sensitivity and 100.0% specificity. The PPR mixes remained stable over 30 working days, with no significant CT value changes. This study confirms the assay’s robust sensitivity, specificity, reproducibility, and accuracy for both nasal and 3-point screening swabs. IMPORTANCE: Candida auris is a multidrug-resistant yeast responsible for severe infections with high mortality rates. Rapid and accurate detection is critical for preventing the spread of this pathogen in healthcare settings. This study assesses the performance of an automated real-time PCR screening assay for detecting C. auri s using nasal and 3-point swabs. The findings demonstrate the assay's high sensitivity, specificity, and reproducibility, making it a valuable tool for infection control. By providing a reliable and efficient screening method, this assay can significantly enhance efforts to control C. auris outbreaks, ultimately improving patient outcomes and reducing the spread of this dangerous pathogen.
- 1 April 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (4)
Open AccessPerformance characteristics of an automated, high-throughput RT-PCR assay for the detection of Candida auris on 3-point and nasal swabs
Candida auris is a multidrug-resistant yeast responsible for invasive infections with high mortality rates, primarily spread through prolonged colonization on biotic and abiotic surfaces and traveling. Effective control necessitates comprehensive screening protocols, as recommended by the Centers for Disease Control and Prevention, which endorses a real-time polymerase chain reaction-based assay for C. auris screening. This study evaluates the performance of this assay on the Hologic Panther Fusion System using nasal and 3-point swab specimens (nares/axilla/groin) compared with culture. The assay was assessed for accuracy, sensitivity, specificity, and reproducibility, alongside an evaluation of probe primer reagent (PPR) onboard stability over 30 working days. Analytical sensitivity studies determined limits of detection of 1.95 Log CFU/mL for nasal swabs and 2.18 Log CFU/mL for 3-point swabs, both with >95.0% confidence intervals. The assay demonstrated 100% specificity ( n = 25), with no false positives from genetically similar or clinically relevant species, and no significant interference from co-infecting microbes on cycle threshold (CT) values. Both swab types exhibited high intra- and inter-reproducibility, with low coefficients of variation (1.79% and 1.06%, respectively). The assay detected C. auris in 100% of 108 spiked-positive samples across both swab types. Clinical analysis showed 100% concordance with culture for 3-point swabs. Additionally, the nasal swab method showed 96.0% overall agreement, with 86.2% sensitivity and 100.0% specificity. The PPR mixes remained stable over 30 working days, with no significant CT value changes. This study confirms the assay’s robust sensitivity, specificity, reproducibility, and accuracy for both nasal and 3-point screening swabs. IMPORTANCE: Candida auris is a multidrug-resistant yeast responsible for severe infections with high mortality rates. Rapid and accurate detection is critical for preventing the spread of this pathogen in healthcare settings. This study assesses the performance of an automated real-time PCR screening assay for detecting C. auri s using nasal and 3-point swabs. The findings demonstrate the assay's high sensitivity, specificity, and reproducibility, making it a valuable tool for infection control. By providing a reliable and efficient screening method, this assay can significantly enhance efforts to control C. auris outbreaks, ultimately improving patient outcomes and reducing the spread of this dangerous pathogen.
- 2 April 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (8) , 743-747
Skin and Soft Tissue Actinomycosis in Children and Adolescents
Background: Pediatric actinomycosis studies are limited to case reports or small case series. In this retrospective cohort study, we aimed to describe characteristics of skin and soft tissue actinomycosis in adolescents and children. Methods: We conducted the study from January 2019 to December 2022, including patients ≤21 years of age with at least 1-year follow-up data. All clinical cultures obtained under sterile conditions with Actinomyces growth were included. Results: One hundred four patients met inclusion criteria; median age 19 (interquartile range: 17–20) years, 68.3% female, 46.2% Black and 47.1% Hispanic. The median antibiotic treatment duration was 10 (7–10) days, and majority of patients received treatment with non-first-line Actinomyces antibiotics. Infectious disease consultation was requested for only 7 patients during their initial skin and soft tissue actinomycosis treatment. One-third of the patients with skin and soft tissue actinomycosis had documented recurrence within a median of 10 (interquartile range: 6–16) months of the initial episode. Monobacterial culture growth (85.7% vs. 63.8%, P = 0.02), patients with body mass index >25 (75% vs. 52.6%, P = 0.04) and patients with prior abscess in the same area (18.8% vs. 51.4%, P = 0.001) were significantly higher in patients with recurrent actinomycosis compared to the nonrecurrent group. In a univariate logistic regression model, they were found to be significantly associated with recurrence; monobacterial growth [odds ratio (OR): 3.4; 95% confidence interval (CI): 1.2–9.9], body mass index >25 (OR: 2.7; 95% CI, 1.1–7.0) and prior abscess (OR: 4.6; 95% CI: 1.9–11.2). Conclusions: Our study results highlight the importance of considering Actinomyces species in skin and soft tissue infections, especially in recurrent ones, and risk factors for recurrence. Suboptimal antibiotic utilization, very low numbers of consultations with infectious diseases and high recurrence rate suggest that providers should be informed and updated regarding this rare but hard-to-treat infection.
- 2 April 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (8) , 743-747
Skin and Soft Tissue Actinomycosis in Children and Adolescents
Background: Pediatric actinomycosis studies are limited to case reports or small case series. In this retrospective cohort study, we aimed to describe characteristics of skin and soft tissue actinomycosis in adolescents and children. Methods: We conducted the study from January 2019 to December 2022, including patients ≤21 years of age with at least 1-year follow-up data. All clinical cultures obtained under sterile conditions with Actinomyces growth were included. Results: One hundred four patients met inclusion criteria; median age 19 (interquartile range: 17–20) years, 68.3% female, 46.2% Black and 47.1% Hispanic. The median antibiotic treatment duration was 10 (7–10) days, and majority of patients received treatment with non-first-line Actinomyces antibiotics. Infectious disease consultation was requested for only 7 patients during their initial skin and soft tissue actinomycosis treatment. One-third of the patients with skin and soft tissue actinomycosis had documented recurrence within a median of 10 (interquartile range: 6–16) months of the initial episode. Monobacterial culture growth (85.7% vs. 63.8%, P = 0.02), patients with body mass index >25 (75% vs. 52.6%, P = 0.04) and patients with prior abscess in the same area (18.8% vs. 51.4%, P = 0.001) were significantly higher in patients with recurrent actinomycosis compared to the nonrecurrent group. In a univariate logistic regression model, they were found to be significantly associated with recurrence; monobacterial growth [odds ratio (OR): 3.4; 95% confidence interval (CI): 1.2–9.9], body mass index >25 (OR: 2.7; 95% CI, 1.1–7.0) and prior abscess (OR: 4.6; 95% CI: 1.9–11.2). Conclusions: Our study results highlight the importance of considering Actinomyces species in skin and soft tissue infections, especially in recurrent ones, and risk factors for recurrence. Suboptimal antibiotic utilization, very low numbers of consultations with infectious diseases and high recurrence rate suggest that providers should be informed and updated regarding this rare but hard-to-treat infection.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1814. Retrospective Study of Skin and Soft Tissue Actinomycosis in an Urban Pediatric Academic Medical Center
Actinomyces species are known colonizers of human mucosal surfaces but are rarely associated with disease in immunocompetent hosts. Pediatrics studies are limited to case reports. This retrospective study aims to describe the characteristics of skin and soft tissue actinomycosis (SSTA) and the frequency and risk factors of recurrence in pediatric patients. Our findings suggest that patients with SSTA were generally adolescents with elevated BMI. Monobacterial culture growth, BMI >25, and prior abscess in the same area were significantly associated with recurrence. High recurrence rate, suboptimal antibiotic utilization and very low rates of consultation with infectious diseases suggest that providers should be informed and updated regarding this rare but difficult to treat infection. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1814. Retrospective Study of Skin and Soft Tissue Actinomycosis in an Urban Pediatric Academic Medical Center
Actinomyces species are known colonizers of human mucosal surfaces but are rarely associated with disease in immunocompetent hosts. Pediatrics studies are limited to case reports. This retrospective study aims to describe the characteristics of skin and soft tissue actinomycosis (SSTA) and the frequency and risk factors of recurrence in pediatric patients. Our findings suggest that patients with SSTA were generally adolescents with elevated BMI. Monobacterial culture growth, BMI >25, and prior abscess in the same area were significantly associated with recurrence. High recurrence rate, suboptimal antibiotic utilization and very low rates of consultation with infectious diseases suggest that providers should be informed and updated regarding this rare but difficult to treat infection. All Authors: No reported disclosures
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
555. Clinical impact and real-life utilization of Karius testing: a retrospective analysis of cases from an urban, academic medical center
Metagenomic next-generation sequencing (NGS) of microbial cell-free DNA is a relatively novel diagnostic technique that may potentially expedite and/or supplement pathogen-specific infectious disease diagnoses, minimize the time to appropriate antibiotic therapy, and reduce unnecessary and invasive testing. However, careful diagnostic stewardship is necessary to ensure that such tests are being ordered in the appropriate patient population. A retrospective chart review of all patients for whom the Karius NGS test was sent at our institution between Jun 13, 2020-Jul 22, 2022 was performed. Clinically relevant pathogens were defined as diagnoses that led to change in antimicrobial therapy. Stata statistical software (version 17.0, College Station TX) was used to analyze patient and hospitalization risk factors associated with Karius testing. Thirty cases among 29 unique patients for whom Karius testing was performed were included in our review. Patient characteristics are shown in Table 1. Twenty-one patients (72%) were immunocompromised, including 14 (47%) with solid organ transplant (SOT) and 9 (30%) with malignancy. Mean hospital length of stay (LOS) prior to Karius test collection was 15.8 days (+/- 21.6 days, range 1-120). Reasons for sending Karius are shown in Fig 1. Three patients (10%) had tissue-specific NGS testing performed in addition to Karius. On average, patients received 13.9 days of antibiotics prior to Karius (+/-10.11, range 0-37). Mean turnaround time for Karius results was 38.3 hours (+/- 16.5, range 23-79). Ten (34.5%) Karius results identified no pathogens. Karius identified fungal organisms in 3 (10%) tests, one of which correlated with true infection. Karius results correlated with other infectious diagnostics (such as viral PCR or cultures) in 10 (33%) cases. Clinically relevant pathogens (not identified by other testing) were identified by Karius in only 3 (10%) cases. There was no statistically significant correlation between pathogen detection by Karius and history of HIV (p=0.27), transplant (p=0.70), malignancy (p= 0.21), or number of days from admission to test (p=0.66) Patient characteristics (N=29 unique patients, 30 tests) Reasons for Karius test Metagenomic NGS is an exciting area of diagnostic innovation, but more studies are needed to determine when and where this test is best utilized. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access555. Clinical impact and real-life utilization of Karius testing: a retrospective analysis of cases from an urban, academic medical center
Metagenomic next-generation sequencing (NGS) of microbial cell-free DNA is a relatively novel diagnostic technique that may potentially expedite and/or supplement pathogen-specific infectious disease diagnoses, minimize the time to appropriate antibiotic therapy, and reduce unnecessary and invasive testing. However, careful diagnostic stewardship is necessary to ensure that such tests are being ordered in the appropriate patient population. A retrospective chart review of all patients for whom the Karius NGS test was sent at our institution between Jun 13, 2020-Jul 22, 2022 was performed. Clinically relevant pathogens were defined as diagnoses that led to change in antimicrobial therapy. Stata statistical software (version 17.0, College Station TX) was used to analyze patient and hospitalization risk factors associated with Karius testing. Thirty cases among 29 unique patients for whom Karius testing was performed were included in our review. Patient characteristics are shown in Table 1. Twenty-one patients (72%) were immunocompromised, including 14 (47%) with solid organ transplant (SOT) and 9 (30%) with malignancy. Mean hospital length of stay (LOS) prior to Karius test collection was 15.8 days (+/- 21.6 days, range 1-120). Reasons for sending Karius are shown in Fig 1. Three patients (10%) had tissue-specific NGS testing performed in addition to Karius. On average, patients received 13.9 days of antibiotics prior to Karius (+/-10.11, range 0-37). Mean turnaround time for Karius results was 38.3 hours (+/- 16.5, range 23-79). Ten (34.5%) Karius results identified no pathogens. Karius identified fungal organisms in 3 (10%) tests, one of which correlated with true infection. Karius results correlated with other infectious diagnostics (such as viral PCR or cultures) in 10 (33%) cases. Clinically relevant pathogens (not identified by other testing) were identified by Karius in only 3 (10%) cases. There was no statistically significant correlation between pathogen detection by Karius and history of HIV (p=0.27), transplant (p=0.70), malignancy (p= 0.21), or number of days from admission to test (p=0.66) Patient characteristics (N=29 unique patients, 30 tests) Reasons for Karius test Metagenomic NGS is an exciting area of diagnostic innovation, but more studies are needed to determine when and where this test is best utilized. All Authors: No reported disclosures
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (11) , 3247-3251
Detection and genetic characterization of community-based SARS-CoV-2 infections – New York City, March 2020
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (11) , 3247-3251
Open AccessDetection and genetic characterization of community-based SARS-CoV-2 infections – New York City, March 2020
- Open Access
- 21 June 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e98
Does local matter? Evaluating susceptibility variations between hospital-wide and hematology-oncology unit antibiograms
Antibiograms are important for guiding empiric antibiotics for febrile neutropenia. However, hospital-wide antibiograms may not capture complexities of patients with hematologic malignancies. We created a hematology-oncology unit-specific antibiogram and found higher resistance among Escherichia coli, Klebsiella pneumonia, and Enterococcus isolates compared to hospital-wide data.
- 21 June 2022
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 2 (1) , e98
Open AccessDoes local matter? Evaluating susceptibility variations between hospital-wide and hematology-oncology unit antibiograms
Antibiograms are important for guiding empiric antibiotics for febrile neutropenia. However, hospital-wide antibiograms may not capture complexities of patients with hematologic malignancies. We created a hematology-oncology unit-specific antibiogram and found higher resistance among Escherichia coli, Klebsiella pneumonia, and Enterococcus isolates compared to hospital-wide data.
- 1 November 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 134 (11) , e546-e547
Lung, Brain, and Spinal Cord Abscesses After a Near-Drowning Episode
- 1 November 2021
- Published by Elsevier in The American Journal of Medicine
- Vol. 134 (11) , e546-e547
Lung, Brain, and Spinal Cord Abscesses After a Near-Drowning Episode
- Open Access
- 28 April 2021
- Published by American Society for Microbiology in mSphere
- Vol. 6 (2)
Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts
Serological surveillance has become an important public health tool during the COVID-19 pandemic. Detection of protective antibodies and seroconversion after SARS-CoV-2 infection or vaccination can help guide patient care plans and public health policies.
- 28 April 2021
- Published by American Society for Microbiology in mSphere
- Vol. 6 (2)
Open AccessSingle-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts
Serological surveillance has become an important public health tool during the COVID-19 pandemic. Detection of protective antibodies and seroconversion after SARS-CoV-2 infection or vaccination can help guide patient care plans and public health policies.